ABL1	Translocations predict sensitivity to TKIs like imatinib, dasatinib, nilotinib.  Secondary mutations can cause resistance	Imatinib, Dasatinib, Nilotinib
AKT1	Mutations may predict sensitivity to AKT/MTOR inhibitors	AKT/MTOR inhibitors
AKT2	Mutations may predict sensitivity to AKT/MTOR inhibitors	AKT/MTOR inhibitors
AKT3	Mutations may predict sensitivity to AKT/MTOR inhibitors	AKT/MTOR inhibitors
ALK	Translocations predict sensitivity to crizotinib.  Secondary mutations can cause resistance.  Amplification and activating mutations may also be sensitive to crizotinib	Crizotinib
APC	Biallelic inactivation may predict sensitivity to inhibitors of WNT signaling or anti-TRAIL antibodies. Also prognostic/diagnostic due to germline mutations	WNT inhibitors
AR	Amplification may predict resistance to androgen deprivation in prostate cancer and may predict sensitivity to MDV3100	"Andorgen. Deprivation MDV3100"
ARAF	Activating mutations may predict sensitivity to sorafenib	Sorafenib
ASXL1	Prognostic in MDS	NA
ATM	Biallelic inactivation predict sensitivity to PARP inhibitors	PARP Inhibitor
ATR	Biallelic inactivation predict sensitivity to PARP inhibitors	PARP Inhibitor
AURKA	Amplifications are prognostic in colon cancer.  Also a target of Therapy	AURKA Inhibitor
BAP1	Biallelic inactivation may predict sensitivity to HDAC inhibitors	HDAC Inhibitors
BCL2	Translocation is prognostic/diagnostic in some hematologic cancers and activating alterations may be sensitive to BCL2 inhibitors	? BCL2 inhibitors
BRAF	Mutations predict sensitivity to RAF inhibitors. Amplification may predict resistance to MEK inhibitors.	"Vemurafenib MEK inhibitors"
BRCA1	Biallelic inactivation predict sensitivity to PARP inhibitors. Also prognostic/diagnostic due to germline mutations.	PARP Inhibitor
BRCA2	Biallelic inactivation predict sensitivity to PARP inhibitors. Also prognostic/diagnostic due to germline mutations.	PARP Inhibitor
BRD2	Sensitivity to HDAC inhibitors, bromodomain inhibitors	"HDAC Inhibitors. Bromodomain inhibitors"
BRD3	Sensitivity to HDAC inhibitors, bromodomain inhibitors	"HDAC Inhibitors. Bromodomain inhibitors"
BRD4	Sensitivity to HDAC inhibitors, bromodomain inhibitors	"HDAC Inhibitors. Bromodomain inhibitors"
CCND1	Amplification may predict resistance to hormone therapy in breast cancer. Amplification may be prognostic in breast cancer.  Amplification may predict sensitivity to CDK4/6 inhibitors. Translocations are diagnostic/prognostic in some hematologic cancers.	"Hormone therapy. CDK 4/6 inhibitor"
CCND2	Amplification may predict sensitivity to CDK4/6 inhibitors.	? CDK inhibitors
CCND3	Amplification may predict sensitivity to CDK4/6 inhibitors.	? CDK inhibitors
CCNE1	Amplification may predict sensitivity to CDK2 inhibitors.	CKD 2 inhibitor
CDH1	Prognostic / Diagnostic	NA
CDK4	Amplification may predict sensitivity to CDK4/6 inhibitors.	CDK 4/6 inhibitor
CDK6	Amplification may predict sensitivity to CDK4/6 inhibitors.	CDK 4/6 inhibitor
CDKN1A	Deletion may predict sensitivty to CDK inhibitors	CDK 4/6 inhibitor
CDKN1B	Deletion may predict sensitivty to CDK inhibitors	CDK 4/6 inhibitor
CDKN2A	Biallelic inactivation may predict sensitivity to CDK4/6 inhibitors.	CDK 4/6 inhibitor
CDKN2B	Biallelic inactivation may predict sensitivity to CDK4/6 inhibitors.	CDK 4/6 inhibitor
CEBPA	Biallelic inactiavtion is an indication for transplant in AML. Sensitivity to CDK inhibitors	Transplant
CREBBP	Biallelic inactivation is Prognostic / Diagnostic in leukemia	CDK 4/6 inhibitor
CRKL	Amplification may result in resistance to EGFR inhibition and RAF inhibition. Amplification may predict sensitivity to SRC inhibitors.	Vemurafenib; SRC inhibitors
CTNNB1	Possibly prognostic in colon cancer; maybe some resistance stuff in lung cancer and melanoma; possibly targetable with WNT inhibitors (see APC above) <NEED TO FILL IN>	? WNT inhibitors
DDR2	Mutations may predict sensitivity to dasatinib (see Hammerman Cancer Discovery paper)	Dasatinib
DNMT3A	Some mutations may be sensitive to DNA methylransferace inhibitors.  Some may be prognostic in leukemia	DNAMT inhibitors
EGFR	Mutations targetable with TKIs (both FDA approved and novel). Other mutations predict resistance to TKIs.  Amplification associated with response to anti-EGFR Abs in colon cancer. Amplification also associated with resistance to TKIs in some cancers.  Rearangement is prognostic in GBM, HNSCC	"Erlotinib, Gefitinib. Novel EGFR Inhibitors"
EPHA3	Alterations may predict sensitivity to dasatinib	Dasatinib
EPHA5	Alterations may predict sensitivity to dasatinib	Dasatinib
ERBB2	Amplifications predict sensitivity to anti-Her2 therapy. <what about mutations?>	Trastuzumab, Lapatinib
ERBB3	Alterations may be sensitive to pertuzumab or novel HER3 inhibitors	Pertuzumab
ERBB4	Mutations may predict sensitivity to Lapatinib and other anti-EGF family inhibitors	Lapatinib
ERG	Fusion with TMPRSS2 shown to potentiate sensitivity to PARP inhibitors in vitro (Brenner JC, Cancer Cell, 2011)	PARP Inhibitor
ESR1	Amplification may predict ER positivity in breast cancer	Hormonal therapy
ETV1	Diagnostic	NA
ETV4	Diagnostic	NA
ETV5	Diagnostic	NA
ETV6	Diagnostic	NA
EWSR1	Diagnostic	NA
EZH2	Negative prognostic factor in MDS.  Targetable with EZH2 inhibitors, in development.	? HDAC inhibitor?
FBXW7	Mutation or loss may predict sensitivity to MTOR inhibitors.  Mutations or loss may predict resistance to anti-tubulin chemotherapy	"MTOR inhibitors. Tubulins"
FGFR1	Amplification predicts resistance to hormonal therapy in breast cancer.  Amplification predicts sensitivity to FGFR inhibitors	FGFR Inhibitors
FGFR2	Alterations may predict sensitivity to FGFR inhibitors	FGFR Inhibitors
FGFR3	Alterations may predict sensitivity to FGFR inhibitors	FGFR Inhibitors
FLT3	Mutations predict sensitivity to FLT3 inhibitors, sunitinib.  Secondary mutations predict resistance.	Sunitinib, FLT3 inhibitors
GNA11	Mutations may predict sensitivity to MAPK pathway inhibitors	MAPK pathway inhibitors
GNAQ	Mutations may predict sensitivity to MAPK pathway inhibitors	MAPK pathway inhibitors
GNAS	Mutations may be diagnostic of tumors arising in McCune-Albright syndrome, and may be targetable with JAK inhibitors	JAK inhibitors
HRAS	Mutations may predict sensitivity to MAPK pathway inhibitors.  Mutations may predict resistance to TKIs.	MAPK pathway inhibitors
IDH1	Prognostic / Diagnostic	<in development>
IDH2	Prognostic / Diagnostic	<in development>
IGF1R	Amplification may predict senitivity to IGFR1-R inhibitors	IFG1-R Inhibitor
JAK2	Mutations may predict sensitivity to JAK2 inhibitors	JAK inhibitors
JAK3	Mutations may predict sensitivity to JAK3 inhibitors	JAK inhibitors
KDR	Activating mutations may predict sensitivity to specific inhibitors	KDR inhibitors
KIT	Mutations targetable with TKIs (both FDA approved and novel). Secondary mutations predict resistance to TKIs.  Amplification also associated with resistance to TKIs.	"Imatinib, Sunitinib. Novel KIT Inhibitors"
KRAS	Mutations may predict resistance to anti-EGFR therapies (cetuximab, ant-EGFR TKIs).  Mutations may predict sensitivity to MEK inhibitors.  Mutations may be directly targetable by some therapies (immunotherapies, viruses).  Prognostic in some cancer types.	"Cetuximab. MEK inhibitors"
MAP2K1	Mutations predict resistance to RAF- and MEK- inhibitor	Vemurafenib, MEK inhibitors
MAP2K2	Activating mutations may predict sensitivty to MEK2 inhibitors	MEK2 inhibiros
MAP2K4	Orthologue of Targetable, CGC	MAP2K4 inhibitors
MCL1	Amplification may predict resistance to anti-tubulin chemotherapy	Tubulins
MDM2	Amplification may predict sensitivity to Nutlins and MDM2 inhibitors	Nutlin
MDM4	Amplification may predict sensitivity to Nutlins and MDM4 inhibitors	? Nutlin
MEN1	Prognostic / Diagnostic (also germline)	NA
MET	Amplification may cause resistance to anti-EGFR TKIs.  Amplification may predict sensitivity to MET-inhibitors	"Gefitinib, Erlotinib. MET inhibitors"
MITF	Prognostic / Diagnostic (also germline)	NA
MLH1	Prognostic / Diagnostic in colon cancer	NA
MLL	Translocations are prognostic / diagnostic. Alterations may be sensitive to HDAC inhibitors or novel inhibitors in development	HDAC Inhibitors
MPL	Mutation may predict sensitivity to JAK2 inhibitor	JAK2 inhibitors
MSH2	Prognostic / Diagnostic in colon cancer	NA
MSH6	Prognostic / Diagnostic in colon cancer	NA
MTOR	Activating mutations may predict sensitivity to MTOR inhibitors	MTOR inhibitors
MYC	Prognostic / Diagnostic 	NA
NF1	Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors (PI3K/AKT/MTOR) and/or MAPK pathway inhibitors (RAF/MEK/ERK).	"PI3K/AKT/MTOR inhibitors. RAF/MEK/ERK inhibitors"
NF2	? Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors (PI3K/AKT/MTOR) and/or MAPK pathway inhibitors (RAF/MEK/ERK).	"PI3K/AKT/MTOR inhibitors. RAF/MEK/ERK inhibitors"
NFKBIA	Deletion is prognostic in GBM	NA
NKX2-1	Diagnostic	NA
NOTCH1	Activating mutations and rearrangements may predict sensitivity to Notch inhibitors	Notch Inhibitors
NOTCH2	Activating mutations may predict sensitivity to Notch inhibitors	Notch Inhibitors
NPM1	Mutations are an indication for transplant in AML	Transplant
NRAS	Mutations predict resistance to RAF- inhibitors	"? Vemurafenib"
NTRK3	Fusion with ETS factors (in secretory breast cancer, for example) may predict sensitivity to PI3K pathway inhibitors, SRC inhibitors, and/or IGF1-R inhibitors	"PI3K/AKT/MTOR inhibitors. Dasatinib or other src inhibitors. IGF1-R inhibitors"
NUT	Sensitivity to HDAC inhibitors, bromodomain inhibitors	"HDAC Inhibitors. Bromodomain inhibitors"
PDGFRA	Mutations predict sensitivity to imatinib	Imatininb
PDGFRB	Alterations predict sensitivity to imatinib	Imatininb
PIK3CA	Mutations may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors.  Mutations may predict resistance to anti-RTK therapy, including cetuximab, anti-EGFR TKIs, and trastuzumab and lapatinib	PI3K/AKT/MTOR inhibitors
PIK3R1	Mutations may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors.	PI3K/AKT/MTOR inhibitors
PTCH1	Mutations may predict sensitivity to hedgehog inhibitors	Vismodegib
PTEN	Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors.  Biallelic inactivation may predict resistance to anti-RTK therapy, including cetuximab, anti-EGFR TKIs, and trastuzumab and lapatinib.  Biallelic inactivation may predict sensitivity to PARP inhibitors	PI3K/AKT/MTOR inhibitors
RAF1	Alterations may predict sensitivity to RAF inhibitors.  Amplification may predict resistance to specific RAF inhibitors (like vemurafenib). 	"Sorafenib. RAF inhibitors"
RARA	Transloactions predict sensitivity to ATRA and arsenic	ATRA, Arsenic
RB1	Prognostic / Diagnostic (germline)	NA
RET	Mutations and fusion may predict sensitivity to RET inhibitors	"Sorafenib, vandetinib. Other RET Inhibitors"
ROS1	Fusions Sensitive to Crizotinib	Crizotinib
RUNX1	Prognostic / Diagnostic	NA
SMAD2	Prognostic / Diagnostic in colon cancer	NA
SMAD4	Prognostic / Diagnostic in colon cancer	NA
SMARCA4	Inactivation may predict sensitivity to HDAC inhibitors	HDAC
SMARCB1	Inactivation may predict sensitivity to CDK Inhibitors, Hedgehog Inhibitors, and/or HDAC Inhibitors	"CDK inhibitors. Vismodegib. Hedgehog inhibitors. HDAC inhibitors"
SMO	Mutations may predict sensitivity to hedgehog inhibitors	Vismodegib
STK11	Biallelic inactivation may predict sensitivity to MTOR inhibitors.  Biallelic inactiavtion may predict sensitivity to SRC or FAK inhibitors (Cancer Cell 2010)	"MTOR inhibitors. Dasatinib. FAK inhibitors"
SYK	Activating mutations may predict sensitivity to Syk inhibitors	SYK inhibitors
TET2	Prognostic / Diagnostic in MDS 	NA
TMPRSS2	Prognostic / Diagnostic	NA
TP53	Biallelic inactivation or mutation may be prognostic in some tumor types.  They may also predict sensitivity to some p53 specific gene therapies or immunotherapies 	Anti-p53 therapies
TSC1	Biallelic inactivation may predict sensitivity to MTOR inhibitors	MTOR inhibitors
TSC2	Biallelic inactivation may predict sensitivity to MTOR inhibitors	MTOR inhibitors
VHL	Prognostic / Diagnostic (germline)	NA
WT1	Prognostic / Diagnostic (germline)	NA
XPO1	Mutations may predict sensitivity to small molecule selective inhibitors of nuclear export (SINE) 	SINE agents
c15orf55	Sensitivity to HDAC inhibitors, bromodomain inhibitors	HDAC inhibitors